India, July 31 -- Shares of Alnylam Pharmaceuticals, Inc. (ALNY) were surging around 18% in the mid-day trading on the Nasdaq, after the RNAi therapeutics company raised its fiscal 2025 outlook after reporting higher second-quarter revenues. Meanwhile, the company recorded wider loss in its latest quarter.
For fiscal 2025, the company now expects total net product revenues between $2.65 billion and $2.80 billion, higher than previous estimate of $2.05 billion and $2.25 billion.
The company said the revision of 27% growth in outlook at the mid point reflects the strong progress during the first half of 2025 and the firm's confidence in the overall business for the rest of the year.
The revised outlook reflects an year-over-year growth of ...